Inhaled mannitol as a new mucolytic for treatment of cystic fibrosis
https://doi.org/10.18093/0869-0189-2016-26-6-760-765
Abstract
Mucolytics with efficacy approved for cystic fibrosis (CF) have been reviewed by the authors. Currently, investigators search for new mucoactive agents to improve sputum rheology and expectoration in CF. One the promising mucolytics is inhaled dry powder mannitol which was effective and safe in several international trials. Inhaled mannitol has been implemented in clinical practice for CF treatment in some countries. Therefore, goals of new studies should be optimization the use, determination the target population and investigation of combined therapy with different mucolytics in CF.
About the Authors
Yu. V. Gorinova
Federal Academic Centre of Children's Health, Healthcare Ministry of Russia
Russian Federation
Russian Federation
Lomonosovskiy pr. 2, build. 1, Moscow, 119991, Russia
Candidate of Medicine, Senior Researcher at Division of Pulmonology and Allergy, Federal Academic Centre of Children's Health, Healthcare Ministry of Russia; tel.: (499) 1349331
S. A. Krasovskiy
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
ul. Odinnadtsataya Parkovaya 32, build. 4, Moscow, 105077, Russia;
ul. Odinnadtsataya Parkovaya 32, build. 4, Moscow, 105077, Russia
Candidate of Medicine, Senior Researcher at Laboratory of Cystic Fibrosis, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; pneumologist at the 2nd Pulmonology Department, D.D.Pletnev City Clinical Hospital, Moscow Healthcare Department; Senior Researcher at Research and Clinical Division of Cystic Fibrosis, Federal Medical Genetic Academic Center, Russian Academy of Science; tel.: (495) 9652324
O. I. Simonova
Federal Academic Centre of Children's Health, Healthcare Ministry of Russia
Russian Federation
Russian Federation
Lomonosovskiy pr. 2, build. 1, Moscow, 119991, Russia
Doctor of Medicine, Head of Department of Pulmonology and Allergology, Federal Academic Centre of Children's Health, Healthcare Ministry of Russia; tel.: (499) 1349331
E. L. Amelina
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Russian Federation
Russian Federation
ul. Odinnadtsataya Parkovaya 32, build. 4, Moscow, 105077, Russia
Candidate of Medicine, Head of Laboratory of Cystic Fibrosis, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; tel.: (499) 7800806
References
1. Kapranov N.I., Kashirskaya N.Yu., eds. Cystic fibrosis. Moscow: MedpraktikaM; 2014 (in Russian).
2. Kashirskaya N.Yu., Krasovskiy S.A., Chernyak A.V. et al. Change in the life expectancy of Moscow patients with cystic fibrosis and its relationship with treatment: a retrospective analysis during 1993 – 2013. Voprosy sovremennoy pediatrii. 2015; 14 (4): 503–508 (in Russian).
3. Krasovskiy S.A., Chernyak A.V., Kashirskaya N.Yu. et al. Cystic fibrosis in Russia: development of the National Register. Pediatriya. Zhurnal im. G.N.Speranskogo. 2014; 93 (4): 44–55 (in Russian).
4. Boucher R.C. Evidence for airway surface dehydration as the initiating event in CF airway disease. J. Int. Med. 2007; 261: 5–16.
5. O’Sullivan B.P., Flume P. The clinical approach to lung disease in patients with cystic fibrosis. Semin. Respir. Crit. Care Med. 2009; 30 (5): 505–513.
6. Flume P.A., Robinson K.A., O’Sullivan B.P. et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir. Care. 2009; 54: 522–537.
7. Kerem E., Conway S., Elborn S., Heijerman H. Standards of care for patients with cystic fibrosis: A European consensus. J. Cyst. Fibrosis. 2005; 4: 7–26.
8. Shah P., Conway S., Scott S. et al. A casecontrolled study with Dornase Alfa to evaluate impact on disease progression over a 4 year period. J. Respiration. 2001; 68: 160–164.
9. Simonova O.I., Gorinova Yu.V. A comparative characteristics of mucolytics in the basic therapy of cystic fibrosis in children. Pediatricheskaya farmakologiya. 2014; 11 (6): 96–103. (in Russian).
10. Fushs H.J., Borowitz D.S., Christiansen D.H. et al. Effect of aerolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N. Engl. J. Med. 1994; 331: 637–642.
11. Mall M., Grubb B.R., Harkema J.R. et al. Increased airway epithelial Na+ absorption produces cystic fibrosislike lung disease in mice. Nat. Med. 2004; 10: 487–493
12. Robinson M., Hemming A.L., Regnis J.A. et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax. 1997; 52: 900–903.
13. Donaldson S.H., Bennett W.D., Zeman K.L. et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N. Engl. J. Med. 2006; 354: 241–250.
14. Elkins M.R., Robinson M., Rose B.R. et al. A controlled trial of longterm inhaled hypertonic saline in patients with cystic fibrosis. N. Engl. J. Med. 2006; 354 (3): 229–240.
15. Wark P., McDonald V.M. Nebulised hypertonic saline for cystic fibrosis. Cochr. Database Syst. Rev. 2009; 2: CD001506.
16. Rosenfeld M., Davis S., Brumback L. Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: Shortterm tolerability, adherence and safety. Pediatr. Pulm. 2011; 46 (7): 666–671.
17. Amin R., Subbarao P., Jabar A. et al. Hypertonic saline improves the LCI in pediatric patients with CF with normal lung function. Thorax. 2010; 65 (5): 379–383.
18. Simonova O.I., Gorinova Yu.V., and Bakradze M.D. Efficacy of inhaled hypertonic solution in children with bronchitis and bronchiolitis. Voprosy sovremennoy pediatrii. 2014; 13 (4): 33–39 (in Russian).
19. Turino G.M., Cantor J.O. Hyaluronan in respiratory injury and repair. Am. J. Respir. Crit. Care Med. 2003; 167: 1169–1175.
20. Buonpensiero P., De Gregorio F., Sepe A. et al. Hyaluronic acid improves ‘‘pleasantness’’ and tolerability of nebulized hypertonic saline in a cohort of patients with cystic fibrosis. Adv. Ther. 2010; 27: 870–878.
21. Heijerman H., Westerman E., Conway S. et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. J. Cyst. Fibros. 2009; 8 (5): 295–315.
22. Ratjen F. Restoring airway surface liquid in cystic fibrosis. N. Engl. J. Med. 2006; 354: 291–293.
23. Hurt K., Bilton D. Inhaled mannitol for the treatment of cystic fibrosis. Exp. Rev. Respir. Med. 2012; 6: 19–26.
24. Anderson S.D., Brannan J., Spring J. A new method for bronchialprovocation testing in asthmatic subjects using a dry powder of mannitol. Am. J. Respir. Crit. Care Med. 1997; 156: 758–765.
25. Daviskas E., Anderson S.D., Brannan J.D. et al. Inhalation of drypowder mannitol increases mucociliary clearance. Eur. Respir. J. 1997; 10: 2449–2454.
26. Pettit R.S., Johnson C.E. Airwayrehydrating agents for the treatment of cystic fibrosis: past, present, and future. Ann. Pharmacother. 2011; 45: 49–59.
27. Bilton D., Robinson P., Cooper P. et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur. Respir. J. 2011; 38: 1071–1080.
28. Aitken M.L., Bellon G., De Boeck K. et al. Longterm inhaled dry powder mannitol in cystic fibrosis: in international randomized study. Am. J. Respir. Crit. Care Med. 2012: 185; 645–652.
29. Bilton D., Bellon G., Charlton B. Pooled analysis of two large randomized phase III inhaled mannitol studies in cystic fibrosis. J. Cystic. Fibros. 2013: 12; 367– 376.
30. Button B.M., Finlayson F., Borg B. Clinical impact of inhaled mannitol in an adult cystic fibrosis population. J. Cyst. Fibros. 2013; 1: S98.
Review
For citations:
Gorinova Yu.V., Krasovskiy S.A., Simonova O.I., Amelina E.L. Inhaled mannitol as a new mucolytic for treatment of cystic fibrosis. PULMONOLOGIYA. 2016;26(6):760-765. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-6-760-765
Views:
2462
Email this article 